Prostate Cancer

Discussing his presentation from the 2023 ASCO Genitourinary Symposium, Neal Shore, MD, FACS, looks at the long-term results of the phase 3 ARAMIS study for patients with nonmetastatic castration-resistant prostate cancer on darolutamide.

Experts addressed ARX788 for patients with HER2-positive breast cancer, and a data update from the update for APEX-01 evaluating ARX517 in patients with prostate cancer was provided during a virtual analyst and investor day.

The secondary analysis of the phase 3 CONDOR study showed that given prior positron emission tomography, piflufolastat F 18 demonstrated changes in intended management, reinforcing the agent's clinical utility.

The PARP inhibitor rucaparib bested physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer in the phase 3 TRITON3 study.

Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.

Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.

At the final analysis of the ARAMIS study, darolutamide reduced the risk of death by 31% compared with placebo in patients with nonmetastatic castration-resistant prostate cancer.

Though not statistically significant, data from the PROpel study of abiraterone acetate and olaparib were noted to be the longest overall survival results seen in a first-line phase 3 trial in metastatic castration-resistant prostate cancer.

Patients with first-line metastatic castration-resistant prostate cancer had improvements in radiographic progression-free survival irrespective of homologous recombination repair status when treated with talazoparib and enzalutamide.

The triplet therapy should become the new standard of care for this patient population, according to recent data.

Treating patients with metastatic castration-resistant prostate cancer with 177Lu-PSMA-617 within 6 months of completing radium showed to be clinically feasible and well tolerated.

Patients treated with darolutamide were less likely to develop disease metastasis or discontinue treatment 6-18 months after treatment initiation compared with enzalutamide or apalutamide.

During a Targeted Oncology™ Case-Based Roundtable™ event, Abhishek Tripathi, MD, discussed with participants their approach to treating patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Nancy Dawson, MD, discussed the treatment of patients with metastatic hormone-sensitive prostate cancer and what important aspects of treatment clinicians should home in on.

The KEYNOTE-991 trial assessing the use of pembrolizumab in combination with enzalutamide and androgen-deprivation therapy has been halted as it failed to reach its primary end points.

In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.

The phase 1 study of ADXS-504 for the treatment of early prostate cancer is ongoing and new patients with be enrolled to test a higher dose level.

Chad Tang discusses where he sees the future of treatment for patients with oligometastatic prostate cancer heading and how the phase 2 EXTEND trial will impact this patient population.

Positive topline results were announced from a study comparing TAVT-45, a formulation of abiraterone acetate that is easier to swallow, to the current formulation.

During a Targeted Oncology case-based roundtable event, J. Paul Monk, MD, discussed dosing and sequencing considerations for the use of cabazitaxel for patients with metastatic castration-resistant prostate cancer.

Radionuclides, such as radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan, now have an added overall survival benefit in metastatic castrate-resistant prostate cancer.

In an interview with Targeted Oncology, Channing J. Paller, MD, discussed the current approaches to radiation therapy, androgen deprivation therapy, and molecular imaging for men with prostate cancer who have biochemical recurrence.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants their experiences with using cabazitaxel in patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.

In an interview with Targeted OncologyTM, Evan Y. Yu, MD, discusses data from the KEYLYNK-010 trial and the future of the combination in prostate cancer.

During a Targeted Oncology case-based roundtable event, Susan Slovin, MD, discussed the next line of therapy for a patient with progressed metastatic castration-resistant prostate cancer with new liver metastasis.